# Cannabis Clinical Research 2026: March 11 Study Update > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-clinical-research-2026-march-11-update/ > **Published:** 2026-03-11T10:16:03-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:09:39-04:00 > **Clinical Summary:** Explore the latest cannabis clinical research 2026 with key study updates from March 11, focusing on evidence-based findings and clinical priorities. --- AM Study UpdateMarch 11, 2026. 20 [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) items from PubMed, sorted by clinical priority. Evidence Watch  |  Nature medicine (2025) Study Summary This phase 3 trial evaluated full-spectrum cannabis extract for chronic low back pain treatment, addressing a condition affecting over 500 million people globally where current pharmacotherapies demonstrate limited efficacy and significant safety concerns. Evidence Watch  |  Acta paediatrica (Oslo, Norway: 1992) (2025) [Cannabinoids for Medical Purposes in Children: A Living Systematic Review.](https://pubmed.ncbi.nlm.nih.gov/40437694/) Study Summary This living systematic review continuously evaluates safety and efficacy data of cannabinoids for pediatric medical use, enabling clinicians to access updated evidence on cannabinoid treatment outcomes in children. [Read more →](https://pubmed.ncbi.nlm.nih.gov/40437694/) Evidence Watch  |  British journal of sports medicine (2026) [Influences on the mental health and well-being of retired professional athletes from high contact team sports: a mixed methods systematic review.](https://pubmed.ncbi.nlm.nih.gov/40930571/) Study Summary for Cannabis Clinicians This systematic review identifies mental health symptoms and influencing factors in retired high contact team sport athletes, potentially informing cannabis treatment considerations for this population’s psychiatric outcomes. [Read more →](https://pubmed.ncbi.nlm.nih.gov/40930571/) Evidence Watch  |  Journal of medical Internet research (2024) [Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial.](https://pubmed.ncbi.nlm.nih.gov/38536225/) Study Finding Summary The Minder mobile intervention showed effectiveness for university students’ mental health and substance use challenges, offering cannabis clinicians a scalable digital tool model for student populations during vulnerable transition periods. [Read more →](https://pubmed.ncbi.nlm.nih.gov/38536225/) Evidence Watch  |  Journal of anxiety disorders (2024) [Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.](https://pubmed.ncbi.nlm.nih.gov/38266511/) This meta-analysis examines whether evidence-based PTSD treatments remain effective for individuals with co-occurring cannabis use and substance use disorders, directly informing clinical treatment decisions. [Read more →](https://pubmed.ncbi.nlm.nih.gov/38266511/) Evidence Watch  |  Annals of the rheumatic diseases (2026) [Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.](https://pubmed.ncbi.nlm.nih.gov/40846590/) Study Summary [Read more →](https://pubmed.ncbi.nlm.nih.gov/40846590/) Evidence Watch  |  International journal of environmental research and public health (2026) [Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.](https://pubmed.ncbi.nlm.nih.gov/41752306/) Study Summary Cannabis flower use showed greater daily anxiety reduction than edibles, suggesting product type influences therapeutic efficacy for [anxiety management](https://cedclinic.com/cannabis-and-ptsd-treatment-memory-loss-benefits/) in clinical populations. [Read more →](https://pubmed.ncbi.nlm.nih.gov/41752306/) Evidence Watch  |  Journal of sleep research (2026) [Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.](https://pubmed.ncbi.nlm.nih.gov/40631525/) Study Summary This pilot trial examined how oral cannabinoids (THC and CBD) affect sleep architecture and daytime function using high-density EEG, providing clinicians evidence-based data on cannabinoid efficacy for insomnia treatment. [Read more →](https://pubmed.ncbi.nlm.nih.gov/40631525/) Evidence Watch  |  Clinical pharmacology and therapeutics (2026) [Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.](https://pubmed.ncbi.nlm.nih.gov/40836528/) CBD showed no direct effect on cortical excitability in this randomized controlled trial, suggesting its anti-seizure benefits in Dravet and Lennox-Gastaut syndromes may operate through mechanisms other than direct cortical modulation. [Read more →](https://pubmed.ncbi.nlm.nih.gov/40836528/) Evidence Watch  |  Journal of psychiatric research (2025) [Pre-trauma insomnia and posttraumatic alcohol and cannabis use in the AURORA observational cohort study of trauma survivors.](https://pubmed.ncbi.nlm.nih.gov/40582081/) Study Finding Summary Pre-trauma insomnia predicted increased posttraumatic cannabis use in trauma survivors, suggesting clinicians should assess insomnia when treating cannabis use disorder in this population. [Read more →](https://pubmed.ncbi.nlm.nih.gov/40582081/) Evidence Watch  |  JAMA health forum (2026) [Adolescent Cannabis Use and Risk of Psychotic, Bipolar, Depressive, and Anxiety Disorders.](https://pubmed.ncbi.nlm.nih.gov/41719031/) Study Finding Summary Adolescent cannabis use is associated with increased risk of psychotic, bipolar, depressive, and anxiety disorders, requiring clinicians to assess cannabis exposure during mental health evaluations in youth populations. [Read more →](https://pubmed.ncbi.nlm.nih.gov/41719031/) Evidence Watch  |  Drug and alcohol dependence (2016) [Anxiety, depression and risk of cannabis use: Examining the internalising pathway to use among Chilean adolescents.](https://pubmed.ncbi.nlm.nih.gov/27427415/) Study Summary Adolescents with internalising symptoms (depression, anxiety) may use cannabis as self-medication; clinicians should screen for and address underlying mental health conditions when treating cannabis use in this population. [Read more →](https://pubmed.ncbi.nlm.nih.gov/27427415/) Evidence Watch  |  Journal of clinical pharmacology (2025) [Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.](https://pubmed.ncbi.nlm.nih.gov/40605143/) Study Summary This systematic review evaluates cannabis derivatives and analogs as potential therapeutic interventions for autism spectrum disorder, assessing clinical evidence for their efficacy in managing autism-related symptoms. [Read more →](https://pubmed.ncbi.nlm.nih.gov/40605143/) Evidence Watch  |  The Journal of clinical psychiatry (2024) [Maternal Cannabis Use in Pregnancy and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in Offspring.](https://pubmed.ncbi.nlm.nih.gov/39724097/) Study Finding Summary Maternal cannabis use during pregnancy is associated with increased risk of autism spectrum disorder or ADHD in offspring, relevant to clinicians counseling pregnant patients on [cannabis safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/). [Read more →](https://pubmed.ncbi.nlm.nih.gov/39724097/) Evidence Watch  |  Addictive behaviors (2026) [Working memory capacity predicts cannabis-induced effects on alcohol urge.](https://pubmed.ncbi.nlm.nih.gov/41275744/) Study Summary for Cannabis Clinicians Working memory capacity predicts individual differences in cannabis’s effects on alcohol craving, suggesting cognitive capacity may help identify patients at risk for altered alcohol use patterns when using cannabis. [Read more →](https://pubmed.ncbi.nlm.nih.gov/41275744/) Evidence Watch  |  Cannabis and [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) (2026) [A Randomized, Open-Label Trial to Assess Feasibility and Tolerability of Topical Cannabis Balms for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS).](https://pubmed.ncbi.nlm.nih.gov/41467893/) Study Summary This trial evaluates whether topical cannabis balms can effectively treat musculoskeletal pain in postmenopausal breast cancer patients using aromatase inhibitors, addressing a common treatment side effect affecting two-thirds of this population. [Read more →](https://pubmed.ncbi.nlm.nih.gov/41467893/) Evidence Watch  |  Psychiatry research. Neuroimaging (2026) [A single dose of cannabidiol modulates the relationship between hippocampal glutamate and learning-related prefrontal activation in individuals at Clinical High Risk of Psychosis.](https://pubmed.ncbi.nlm.nih.gov/41337954/) Study Finding Summary A single CBD dose modulated the relationship between hippocampal glutamate and prefrontal brain activation during learning tasks in individuals at clinical high risk for psychosis, suggesting a potential neurobiological mechanism relevant to psychosis prevention. [Read more →](https://pubmed.ncbi.nlm.nih.gov/41337954/) Evidence Watch  |  Medicine and science in sports and exercise (2026) [Daily Use of a Broad-Spectrum Cannabidiol Supplement Produces Detectable Concentrations of Cannabinoids in Urine Prohibited by the World Anti-Doping Agency: An Effect Amplified by Exercise.](https://pubmed.ncbi.nlm.nih.gov/40920736/) Study Finding Summary Broad-spectrum CBD supplements contain prohibited cannabinoids that accumulate in urine with daily use and exercise, potentially causing positive WADA drug tests despite CBD’s legal status. [Read more →](https://pubmed.ncbi.nlm.nih.gov/40920736/) Evidence Watch  |  Journal of neurodevelopmental disorders (2025) [Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study.](https://pubmed.ncbi.nlm.nih.gov/41254489/) Study Summary ZYN002, a transdermal cannabidiol gel, demonstrated long-term safety and tolerability in pediatric FXS patients, providing clinical evidence for cannabidiol’s potential therapeutic application in this genetic disorder characterized by dysregulated endocannabinoid signaling. [Read more →](https://pubmed.ncbi.nlm.nih.gov/41254489/) Clinical Commentary Dr. Caplan’s Take Clinical Reflection These studies collectively demonstrate that [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) is transitioning from symptomatic relief toward mechanism-based, population-specific application, with particular promise in pain syndromes and anxiety disorders while flagging significant safety concerns in vulnerable populations including adolescents, pregnant women, and those with underlying psychiatric vulnerability. The evidence increasingly suggests that cannabinoid formulation type (flower vs. edible), cannabinoid ratio (THC:CBD balance), and individual risk stratification are as clinically relevant as the compounds themselves, requiring more nuanced prescribing frameworks than current practice often reflects. My responsibility as a cannabis-knowledgeable physician is to move beyond permissive attitudes toward therapeutic use and instead adopt the same rigorous risk-benefit analysis I apply to other medications, particularly regarding developmental windows and psychiatric comorbidities where the data signal real harm. CannabisMental HealthSubstance Use DisordersSleep And Neurological HealthAdolescent Health 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/mental-health/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Study+Digest+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Study+Digest+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/41023483/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12705446/)[DOI ↗](https://doi.org/10.1038/s41591-025-03977-0) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [AM Study Update: March 15, 2026](https://cedclinic.com/cannabis-clinical-trials-evidence-march-15-2026/) Continue following the latest cannabis clinical research with the March 15, 2026 update, featuring new study summaries and clinical insights. [Read the March 15 Update](https://cedclinic.com/cannabis-clinical-trials-evidence-march-15-2026/) [AM Study Update: March 16, 2026](https://cedclinic.com/cannabis-research-clinical-update-march-16-2026/) Stay informed with the March 16, 2026 [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) update, providing detailed evidence watch and clinical trial results. [Explore March 16 Findings](https://cedclinic.com/cannabis-research-clinical-update-march-16-2026/) [AM Study Update: March 17, 2026](https://cedclinic.com/full-spectrum-cannabis-extract-chronic-pain-update/) Access the latest cannabis clinical research summaries and evidence-based data from the March 17, 2026 update. [View March 17 Update](https://cedclinic.com/full-spectrum-cannabis-extract-chronic-pain-update/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).